Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ADA: MannKind Has Evolved Rapidly To Accommodate Confident Afrezza Relaunch

Executive Summary

Six months ago it seemed as though the sky was falling for small drug developer MannKind, when its big pharma licensing partner, Sanofi, pulled out of their deal for the manufacture and distribution of approved inhaled insulin therapy, Afrezza. However, MannKind Corp. made rapid changes to evolve its business into a specialty pharmaceutical company and took back the drug to market on its own – a feat it had never performed before.


Related Content

Al Mann Dies, Leaves Legacy Beyond MannKind


Related Companies